Moneyta · stock research · no sign-up needed
INCY
FollowFigures below come straight from SEC filings: every number is the company's own, on the record.
Revenue (Q1 FY2026)
$1.3B
+8.0% y/y
Net income (Q1 FY2026)
$303M
as filed with the SEC
Institutions holding
866
+47 last quarter
Overview · INCYTE CORP
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States, Europe, Japan, and internationally. The company offers JAKAFI (ruxolitinib), for the treatment of adults with intermediate or high-risk myelofibrosis; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), for th…
Management team
- Sheila A. Denton · Executive VP, General Counsel & Corporate SecretaryFind on LinkedIn
- Mr. Ben Strain · Head of Investor RelationsFind on LinkedIn
- Dr. Steven H. Stein M.D. · Executive VP & Chief Medical OfficerFind on LinkedIn
- Dr. Barry P. Flannelly M.B.A., Pharm.D. · Executive VP & GM of North AmericaFind on LinkedIn
Start free to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
What history says when its signals fire
Every signal Moneyta surfaces carries its full base-rate history: how often it beat the index, and how often it didn't. See the evidence
The desk's Snapshot
3 of 15 open to everyone · members see allRead the full desk report on INCY
Seven analysts, the debate, the risk review, every claim cited. And the same for every name you hold.
Free plan, no credit card required. Silver opens the full report, $19.99 a month. AI-written · every claim cites a source · Insight, not advice.
The full desk report
Seven AI analysts read the filings and argue both sides. What survives, with every claim cited, for members.
Who holds it, who's buying Gold
Full holder table, quarter-over-quarter flows, insider transactions, and the conviction screen.
Largest holder
Net flow last quarter
Insider buys, 90d
Further reading
Source: SEC EDGAR (XBRL company facts, form 13F-HR). Educational analysis of published data: insight, not advice.